New Enterprise Associates is a prominent venture capital firm focusing on investments in technology and healthcare startups. They help entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from the seed stage through the IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.

New Enterprise Associates

Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.  JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.

Johnson & Johnson Development Corporation

terling Capital Management is a New Castle-based company offering investment management services to high net-worth clients.

Sterling Capital Management

SightLine Partners manages venture funds that invest in late stage medical technology companies .

SightLine Partners

Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages c.a. €350 M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.

Ysios Capital

DaVita is a provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2012, DaVita operated or provided administrative services at 1,884 outpatient dialysis centers located in the United States, serving approximately 149,000 patients. The company also operated 19 outpatient dialysis centers located in four countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.

DaVita

InterWest invests an average of about $7 - 15 million over the span of their involvement with each company in their portfolio. They invest in companies through the full range of venture investment stages, and investments may be staged over several rounds of financing. Although they generally begin their involvement in the early stages of a company's development, they pursue attractive opportunities based on their individual merits rather than their investment stage.

InterWest Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies.  The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.  Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders.  The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors.  The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.

Frazier Healthcare Partners

BB&T Corporation (NYSE: BBT) is a financial services holding companies in the U.S. with $181.1 billion in assets and market capitalization of $23.8 billion, as of Sept. 30, 2013. Based in Winston-Salem, N.C., the company operates approximately 1,824 financial centers in 12 states and Washington, D.C., and offers a full range of consumer and commercial banking, securities brokerage, asset management, mortgage and insurance products and services. A Fortune 500 company, BB&T is consistently recognized for outstanding client satisfaction by J.D. Power and Associates, the U.S. Small Business Administration, Greenwich Associates and others. BB&T's banking subsidiaries are organized as a group of community banks, each with a regional president, which allows decisions to be made locally, close to the client. This also makes BB&T's client service more responsive, reliable and empathetic.

BB&T

Menlo Park Software offers Software-as-a-Service that assists QMS functions like medical device risk management methods and FDA compliance. The company was founded in 2010 and headquartered in Ann Arbor, Michigan.

Menlo Park Software

Formed in 1982, ABS Ventures is a Boston-based venture capital firm backed by leading global institutional investors. The firm works with exceptional management teams to build industry leading companies in the software, communications and healthcare sectors.   ABS Ventures provides more than just capital. The team brings to bear its collective operational and enterprise-building expertise as well as an extensive network of industry contacts. ABS Ventures works in partnership with management teams and believes that patience and a long term approach drive great performance.

ABS Ventures

Thomas Weisel Venture Partners (TWVP) is an early stage venture capital firm that invests in emerging information technology companies.   As a partner with a long-term perspective, TWVP plays an active role in helping entrepreneurs turn ideas into sustainable businesses. TWVP portfolio companies benefit from the knowledge, energy and resources of the TWVP team and from TWVP's commitment to working with management to build industry-leading companies.

Thomas Weisel Venture Partners

With over $330 million in capital under management, Kearny Venture Partners is a venture capital firm exclusively focused on healthcare products. We believe that the opportunity for entrepreneurs to devise innovative solutions in healthcare has never been greater. Significant unmet needs in healthcare continue to persist, representing large potential market opportunities for safe and effective products. As the molecular basis of disease is increasingly unraveled, new opportunities for intervention emerge. Novel therapies can and will displace incumbent products.

Kearny Venture Partners

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Gilde Healthcare

Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of biology, genomics, and information technology).   Windham seeks to invest in and partner with companies that are commercializing game-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors.   For more information visit: www.windhamvp.com

Windham Venture Partners

GlaxoSmithKline today announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies.   The fund’s first investment will be in SetPoint Medical, a California company considered a trailblazer in creating implantable devices to treat inflammatory diseases.  The fund complements the work of GSK’s Bioelectronics R&D unit, which was established in 2012 after a two-year effort to seek out and engage the most promising researchers in this emerging area of science.   The name of the fund comes from electrical signals called action potentials that pass along the nerves in the body. Irregular or altered patterns of these impulses may occur in association with a broad range of diseases.   GSK believes that miniaturised devices, or bioelectronic medicines, can be designed to read these patterns. The devices could be designed to interface between the peripheral nervous system and specific organs to read, change or generate electronic impulses that help treat disorders as diverse as inflammatory bowel disease or rheumatoid arthritis; respiratory diseases such as asthma and COPD and metabolic diseases including Type 2 diabetes.  The field of bioelectronic medicines is in its very early stages. GSK’s ambition, through collaboration with scientists globally, is to have the first medicine that speaks the electrical language of our body ready for approval by the end of this decade.“We want to help create the medicines of the future and be the catalyst for this work,” said Moncef Slaoui, chairman of R&D and architect of GSK’s early stage investment strategy. “GSK can play the integrating role that is needed to drive this new type of medical treatment all the way from the bench to the patient and this fund is a key part of our efforts.”  Action Potential Venture Capital intends to build a portfolio of five to seven companies over the next five years. The fund will focus investments in three areas:  - New start-up companies that aim to pursue the vision of bioelectronic medicines - Existing companies with technologies that are interacting with the peripheral nervous system  through first-generation devices that can stimulate or block electrical impulses - Companies advancing technology platforms that will underpin these treatment modalities  Action Potential Venture Capital will be based in Cambridge, Massachusetts and managed by a small, dedicated team. The fund has named Imran Eba as its first partner. Imran will move from GSK’s Worldwide Business Development organisation and work closely with the Bioelectronics R&D unit.

Action Potential Venture Capital

The S.H.I.P. team brings more than 50 years of cumulative healthcare experience in investing and operational roles. We have invested globally in more than 60 companies through multiple market cycles. We worked together on a number of healthcare investments over the last 12 years prior to forming S.H.I.P.  We bring a unique set of investing experiences from one of the largest strategic healthcare funds JJDC, which maintains a portfolio of over $1B and annually invests more than $200 million in medical devices, biotech, and consumer health, and private venture investing experiences at Synergy Life Science Partners, a top quartile performing venture capital fund. The S.H.I.P. team has been involved in some of the premium healthcare companies bringing novel technologies to market.

Treo Ventures

Vensana Capital is a venture capital investment firm that focuses on healthcare with breakthrough innovations in medical technology. The firm was founded in 2018 and is based in Minneapolis, Minnesota, United States.

Vensana Capital

Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Nest, SlideShare, and Tudou.

Venrock

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine.   Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Hatteras Venture Partners

CVRx

CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries.  The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing the Barostim, an innovative neuromodulation device for treating heart failure symptoms. The Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, designed to restore balance to the autonomic nervous system, reducing heart failure symptoms. Barostim received FDA approval in 2019 and the CE Mark for heart failure and resistant hypertension in the European Economic Area.

Our Company

Top 5 NASDAQ Medical Device Stocks

CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference - CVRx (NASDAQ:CVRX)

CVRx names Kevin Hykes as CEO

CVRx receives FDA approval for expanded labeling of Barostim

CVRx bolsters its executive ranks with hires from Abbott, Medtronic

CVRx nearly doubles its revenue in Q4

CVRx misses in Q4, wins FDA approval for new IPG

CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024 - CVRx (NASDAQ:CVRX)

Transforming neurological care with innovation

Neurostimulation Tech

CVRx appoints Kevin Ballinger, Mitch Hill to board of directors

CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing the Barostim, an innovative neuromodulation device for treating heart failure symptoms. The Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, designed to restore balance to the autonomic nervous system, reducing heart failure symptoms. Barostim received FDA approval in 2019 and the CE Mark for heart failure and resistant hypertension in the European Economic Area.
In the fourth quarter of 2023, CVRx reported total revenues of USD 10.5 million, a 70% increase over the prior year quarter. For the full year 2023, revenues grew by 72% to USD 22.5 million compared to 2022. The company estimates the US annual market opportunity for Barostim to be USD 2.2 billion, or 76,000 new patients, as of December 2023. In February 2024, CVRx appointed Kevin Hykes, previously CEO of Augmedics, as its new CEO, succeeding the retiring Nadim Yared.

Aleva Neurotherapeutics is a medical device company specializing in deep brain stimulation (DBS) systems for treating neurological disorders such as Parkinson's disease and essential tremor. Based in Lausanne, Switzerland, the company was founded as a spin-off from the Swiss Federal Institute of Technology. Aleva pioneered the development of directional DBS leads with its flagship product, the directSTIM DBS system. This technology aims to deliver more precise electrical stimulation to targeted areas of the brain, potentially improving therapeutic benefits and reducing side effects compared to traditional omnidirectional DBS leads.
The directSTIM system features a novel 12-electrode lead design based on microelectromechanical systems (MEMS) technology. This allows for smoother electrode surfaces and customized shapes optimized for implantation in the brain. The system also incorporates 24 independent current sources, enabling greater flexibility in programming and personalizing stimulation patterns to each patient's unique needs. In May 2024, Aleva received CE marking for the directSTIM system, allowing its commercial launch in Europe.
Aleva's expertise in DBS technology is reflected in its robust intellectual property portfolio, comprising 13 patent families and 90 granted patents related to DBS for neurological and psychiatric disorders. The company aims to transform DBS therapy by combining advanced technologies with shared clinical data to improve surgical experiences and patient outcomes.

Aleva Neurotherapeutics

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company has developed Deep Transcranial Magnetic Stimulation (Deep TMS), a proprietary technology that uses magnetic pulses through a patented H-coil helmet to stimulate deeper and broader brain regions associated with various conditions.
Deep TMS received FDA clearance for treating major depressive disorder (MDD) in 2013, making BrainsWay the first and only TMS company with clinical evidence demonstrating efficacy for this indication. In 2018, the technology obtained FDA clearance for treating obsessive-compulsive disorder (OCD), and in 2021, it was cleared as an aid for short-term smoking cessation.
The Deep TMS treatment is administered through a series of daily sessions over four to six weeks, with each session lasting around 20 minutes. It has been investigated in over 30 randomized clinical trials worldwide, demonstrating its safety and effectiveness. As of April 2021, BrainsWay announced that 100,000 patients have been treated globally with Deep TMS.
In addition to the FDA-cleared indications, BrainsWay is conducting ongoing or planned clinical trials exploring Deep TMS for various psychiatric, neurological, and addiction disorders. The company's commitment to clinical research and building upon its substantial body of evidence positions it as a leader in advancing neuroscience through non-invasive solutions.

Brainsway

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

Cala Health

Cardionomic is a medical device company based in Minneapolis that has developed the Cardiac Pulmonary Nerve Stimulation (CPNS) System, an investigational device designed to treat patients suffering from acute decompensated heart failure (ADHF). The CPNS System consists of a stimulation console and an endovascular catheter that delivers targeted stimulation to the cardiac plexus located in the right pulmonary artery.
The company's approach is founded on the principle that stimulating the autonomic nerves improves a patient's clinical condition by triggering a rebalancing of the autonomic system, shifting it from an imbalanced state into a cycle that enhances the patient's condition even after the therapy is completed. The CPNS System has demonstrated the ability to increase cardiac contractility without significantly affecting heart rate in heart failure patients with reduced ejection fraction.
In January 2024, Cardionomic announced the completion of enrollment in the STIM-ADHF and STOP-ADHF pilot studies, which evaluated the safety and performance of the CPNS System in treating ADHF patients. A total of 35 patients were treated across seven countries. Preliminary results suggest that the CPNS therapy may address the unmet need for more effective treatment options for hospitalized heart failure patients. The pooled data from these studies is planned for publication in early 2024.
The CPNS System leverages engineered electrode surfaces from Pulse Technologies, Inc. to deliver durable electrochemical performance for the neural and cardiac interfacing applications.

Cardionomic

Charco Neurotech was founded in 2019 by Lucy Jung, an industrial designer who was inspired to develop assistive devices for Parkinson's after her own experience as a patient. The CUE1 is a small plastic disc with an electric motor that vibrates at a high frequency in a specialized pattern. This pattern, proven through research, can disrupt the overactive brainwaves that cause Parkinson's symptoms, allowing for improved movement.
The CUE1 attaches to the user's sternum using medical adhesive and is relatively inexpensive compared to other treatments like deep brain stimulation implants. Over 2,000 people in the UK are currently using the CUE1, with a waiting list of almost 20,000 across 120 countries as of March 2024. Charco has raised over USD 10 million in funding and grants, employing around 38 people across the UK, South Korea, and the US.
The device is accompanied by a smartphone app that enables users to personalize the stimulation settings and track their symptoms. Charco aims to obtain regulatory approvals for the CUE1 to be prescribed through healthcare systems like the NHS. In April 2023, Addenbrooke's Hospital in Cambridge became the first hospital to trial the device on inpatients with Parkinson's.
Key customers and partnerships
As of August 2023, over 1,700 people are benefiting from the CUE1 in the UK, and there is a waiting list of over 17,000 people worldwide. Charco has partnered with Dr. Alistair Mackett, a consultant geriatrician at Cambridge University Hospitals, to conduct trials and research on the device's effectiveness.

Charco Neurotech

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

CVRx

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless